Microbiome Company Announces Merger Agreement With Therapeutics Giant
BiomX Merges with Adaptive Phage Therapeutics, Secures $50 Million Financing.
In a significant development in the biotech sector, BiomX Inc. (NYSEAMERICAN: PHGE), a clinical-stage microbiome company, has announced its entry into a merger agreement with Adaptive Phage Therapeutics (APT). The merger is complemented by a concurrent financing deal amounting to $50 million, marking a major milestone for both entities involved. $BiomX (PHGE.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
